APA

Cahn A., Hamblin J. N., Begg M., Wilson R., Dunsire L., Sriskantharajah S., Montembault M., Leemereise C. N., Galinanes-Garcia L., Watz H., Kirsten A. M., Fuhr R. & Hessel E. M. (20180612). Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD. : Pulmonary pharmacology & therapeutics.

Chicago

Cahn A, Hamblin J N, Begg M, Wilson R, Dunsire L, Sriskantharajah S, Montembault M, Leemereise C N, Galinanes-Garcia L, Watz H, Kirsten A M, Fuhr R and Hessel E M. 20180612. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD. : Pulmonary pharmacology & therapeutics.

Harvard

Cahn A., Hamblin J. N., Begg M., Wilson R., Dunsire L., Sriskantharajah S., Montembault M., Leemereise C. N., Galinanes-Garcia L., Watz H., Kirsten A. M., Fuhr R. and Hessel E. M. (20180612). Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD. : Pulmonary pharmacology & therapeutics.

MLA

Cahn A, Hamblin J N, Begg M, Wilson R, Dunsire L, Sriskantharajah S, Montembault M, Leemereise C N, Galinanes-Garcia L, Watz H, Kirsten A M, Fuhr R and Hessel E M. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD. : Pulmonary pharmacology & therapeutics. 20180612.